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1. ABBREVIATIONS
AACE: American Association of Clinical 
Endocrinologists
ADA: American Diabetes Association
AAFP: American Academy of Family 
Physicians
ACP: American College of Physicians
ACCP: American College of Chest Physicians
AGREE Instrument: the Appraisal of 
Guidelines for Research and Evaluation for 
Europe Instrument 
ALP: Alkaline Phosphatase 
ANDEM: Agence Nationale pour le 
Développement de l’Évaluation Médicale 
ASCO: American Society of Clinical 
Oncology 
ATS-ERS: American Thoracic Society and 
European Respiratory Society 
BTS-SCG: British Thoracic Society and 
Society of Cardiothoracic Surgeons of Great 
Britain and Ireland
CEA: Carcinoembryonic Antigen 
CDA: Canadian Diabetes Association
CPG: clinical practice guideline
D: Domain of AGREE Instrument
DM: Diabetes Mellitus 
DNA: Deoxyribonucleic Acid
DS: Domain Score
EBM: Evidence-Based Medicine
EGTM: European Group on Tumour Markers
FNCLCC: Fédération Nationale des Centres 
de Lutte Contre le Cancer
GGT: Gamma-Glutamyl Transferase
GPAC: Guidelines and Protocols Advisory 
Committee
I: Item of AGREE Instrument
ICC: Interclass Correlations
IDF: International Diabetes Federation
IFCC: International Federation of Clinical 
Chemistry and Laboratory Medicine 
Kaiser P: Kaiser Permanente
LD: Lactate Dehydrogenase 
NAC: North America Conference
NACB: National Academy of Clinical 
Biochemistry
NICE: National Institute for Clinical 
Excellence
NHMRC: National Health and Medical 
Research Council
NHS: the National Health Service of the 
United Kingdom
NSCLC: Non-Small Cell Lung Cancer 
NSE: Neuron-Specific Enolase 
NZG: New-Zealand Guidelines Group
PRODIGY: The NHS Clinical Knowledge 
Summaries 
SE: Standard Error
SEMDSA: Society for Endocrinology, 
Metabolism and Diabetes of South Africa.
SGOT: Serum Glutamic-Oxaloacetic 
Transaminase 
SIGN: Scottish Intercollegiate Guidelines 
Network
SOGC: Society of Obstetricians and 
Gynaecologists of Canada
SPLF: Société de Pneumologie de Langue 
Française
TPA: Tissue Polypeptide Antigen
USPSTF: U.S. Preventive Services Task 
Force
WHO: World Health Organisation
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2. INTRODUCTION
The  most  commonly  used  definition  of  evidence-based  medicine (EBM)  is  the 
conscientious,  explicit,  and judicious use of  current  best  evidence  in making decisions 
about the care of the individual patients. The practice of evidence-based medicine means  
integrating individual clinical expertise with the best available external clinical evidence  
from systematic research. In 1997 the Committee of Ministers of the Council of Europe 
recommended the evidence-based guidelines implementing the quality improving system. 
Clinical practice guidelines  aim to for  improve the quality of health care delivery and  
strengthen  the  position  of  the  patient.  According  to  the  definition  of  the  Institute  of 
Medicine, clinical practice guidelines (CPGs) are systematically developed statements to 
assist practitioner and patient decisions about appropriate health care for specific clinical  
circumstances. There  is  an  exponentially  rising  interest  toward  CPGs  in  the  medical 
literature  and  several  organisations  developed  methodological  manuals  or  so-called 
“Guidelines for guidelines”. We found only one relevant narrative review in the literature,  
initiated by the Committee on Evidence-based Laboratory Medicine of the International  
Federation  of  Clinical  Chemistry  and  Laboratory  Medicine  (IFCC),  which  adapted 
methods of evidence-based guideline development to the field of laboratory medicine. This 
review provided an algorithm for the development process and defined specific reporting 
standards  related  to  the  laboratory  aspects  of  diagnostic  recommendations.  Although 
methods for systematic reviewing of the literature and for the development of evidence-
based recommendations, particularly in the field of therapeutics have been published and  
harmonised, the methodological quality of practice guidelines has been widely criticized. 
Most of these CPGs made therapeutic recommendations. Quality of CPGs in diagnostic  
fields and their impact in practice has been less well studied.
3. AIMS AND OBJECTIVES
For our aims we addressed the following key questions: 
• Is  there an easily applicable tool for  the assessment of the quality diagnostic 
CPGs? 
• What is the methodological quality of CPGs especially that of laboratory related 
recommendations?   
• Are diagnostic and therapeutic CPGs different in their methodological quality? 
• Is there any relationship between the characteristics and methodological quality 
of diagnostic CPGs? 
• Do diagnostic CPGs meet basic reporting standards? 
• Is there  any correlation between methodological quality and validity of content 
of CPGs? 
4. METHODS
4.1. Topic selection, search and selection strategy of clinical practice guidelines
For our  investigations  we  have chosen two public health  priority areas  that  have  
implications  for  laboratory  medicine.  One  of  them  was  the  management  of  diabetes 
mellitus (DM). The other topic was related to oncology and focused on the management of 
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non-small-cell-lung-cancer (NSCLC) patients. Systematic literature search was carried out 
in PubMed, in dedicated CPG databases and websites of professional to retrieve diagnostic 
CPGs  published  in  English  between  1  January  1999  and  31  December  2007.  Two 
independent reviewers selected 26 DM and 11 NSCLC CPGs (Figure1). 
Figure 1 Selection of CPGs
 Broad search and selection for laboratory related guidelines in: 
–MEDLINE                                n=222 
–electronic guideline databases  n=295 (overlap 20) 
n = 497 
Excluded for not being relevant to 
the laboratory management of DM 
or NSCLC 
n= 432 
Full articles read for detailed evaluation  
DM CPGs n=54 
NSCLC CPGs n=11 
 
 
Selected for appraisal 
DM CPGs      n=26  
NSCLC CPGs  n=11 
Excluded DM CPGs                 n=28 
• Technical or analytical paper           n=3 
• Duplicate publication                       n=1 
• Inappropiate topic                     n=3 
• No recommendations                       n=4 
• Newer updates available                  n=6 
• Special patient group                        n=2 
• Local protocols                     n=6 
• Parts of one guideline                       n=3 
    (4-part guideline merged into one) 
Excluded NSCLC CPGs           n=0 
 
Screening of titles/ 
abstracts for 
relevance 
 
4.2. Evaluation of the methodological quality of clinical practice guidelines 
4.2.1. Appraisal tool and its applicability to diagnostic guidelines (Paper I) 
We chose the AGREE Instrument a standardized, generic and validated checklist for 
the evaluation of the methodological quality of CPGs. In order to test the applicability of  
AGREE Instrument to diagnostic CPGs and to pilot test the use of this appraisal tool, we  
selected 4 most commonly cited and used primarily diagnostic CPGs for DM. Each CPG 
was independently evaluated by seven assessors and we assessed the agreement between 
reviewers  by statistical  methods  (Cronbach’s  alpha,  Interclass  correlations (ICC)).  The 
four  guidelines  were  compared  using  one-way  ANOVA and  ANOVA  using  repeated 
measurements. The level of significance was defined at p<0.05.
4.2.2. Method  of  appraisal  of  diabetes  mellitus  and  non-small  cell  lung  cancer 
guidelines using the AGREE Instrument 
Each  CPG  was  appraised  by  4  trained  assessors by  the  AGREE  Instrument  as 
described in its manual. We assessed fulfilment of 23 criteria (I) grouped into 6 domains  
on a 4-point Likert scale and calculated Domain Scores (DS) in percentages, than judged  
overall  performance of CPGs with one of 4 options. We appraised the methodological  
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quality  of  NSCLC  CPGs  in  this  way,  except  for  we  changed  the  overall  assessment 
terminology  of  AGREE  (“strongly  recommend”, “recommend  with  provisos  or 
alterations”, “would not recommend”, “unsure”) to “very good”, “good”, “not so good”, or 
“dubious”  because  we  thought  that  this  would  lead to  an easier  understanding  of  the  
relation of methodological quality and content validity.
4.3. Statistical methods 
4.3.1. Correlation between the characteristics and methodological quality of clinical 
practice guidelines
We created subgrouped DM CPGs based on their source, scope, length, origin and 
whether they were supplemented with a guideline methods manual. We also investigated 
the quality of guidelines according to the date and type of publication. In the statistical  
analyses, the mean item (I) and standardized domain scores (DS) of CPG subgroups were  
compared by the Kruskal -Wallis test. The level of significance was set at p≤0.01 because 
of multiple comparisons. All analyses were performed using SPSS for Windows, version 
13. Furthermore, in the DM CPG study we investigated whether the CPG contained 1) an  
evidence table, 2) a description of the grading system, 3) graded recommendations, 4) an 
expiry or review date? We collated data in a table and used descriptive statistics (relative  
frequency). 
4.3.2. Evaluation of differences between primarily diagnostic and combined clinical 
practice guidelines
We created  two  subgroups  of  DM CPGs  based  on  their  scope  for  investigating 
difference  between  “purely  diagnostic”  and  “combined”  CPGs  in  depth  pair-wise 
comparisons were carried out using the Mann-Whitney U test with Bonferroni correction. 
The level of significance was set at p≤0.01 because of multiple comparisons. All analyses 
were performed using SPSS for Windows, version 13. 
4.3.3. Evaluation of the fulfilment of basic diagnostic reporting standards
We assessed the presence of 1) prevalence, 2) diagnostic accuracy of tests, 3) pre-
analytical,  and  4)  analytical  specifications.  The  frequency  of  this  reporting  specific 
laboratory information in different guideline subgroups was compared with the Fisher's  
exact test. The level of significance was set at p≤0.01 because of multiple comparisons. 
All analyses were performed using SPSS for Windows, version 13. 
4.4. Systematic reviewing techniques to compare methodological quality in other 
medical fields
We systematically reviewed the literature that used the AGREE Instrument for such 
evaluation  and compared our findings. We searched electronically in  Medline in  May 
2007 with the following key word combinations: (("Guideline "[Publication Type]  OR 
"Guidelines as Topic"[Mesh] OR "Guideline Adherence"[Mesh] OR "Practice Guideline 
"[Publication Type])  AND quality)  AND AGREE) without  using any language  limits. 
Data on the topics, origin, number and publication dates as well as the AGREE domain 
scores of each study and collected and presented in a summary table and a diagram.
4.5. Methods of the evaluation of relationship between methodological quality and 
validity of content of guidelines
Two assessors extracted all laboratory-related recommendations from the 11 NSCLC 
guidelines selected for review. Validity of recommendations was investigated based on a  
published systematic review regarding the use of tumor markers and other more global 
laboratory tests in NSCLC. Methodological quality was assessed by AGREE Instrument  
with slightly modified expression of overall assessments.
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5. RESULTS
5.1. Applicability of the AGREE Instrument to diagnostic guidelines (Paper I)
The agreement  between  assessors  was  acceptable  based  on  statistical  calculations 
(Table 1). We have noted some discrepancy between statistical judgements of agreement  
and the comparison of each item score of each appraiser therefore we decided not to use 
the calculation of ICC and Cronbach’s alpha in subsequent analysis, but rather we reach  
consensus  for  each  item where  disagreement  is  grater  than  2  scores/item.  In  spite  of 
ANOVA  calculating  similar  ranks  for  the  NICE  and  NACB  CPGs,  by  showing  no 
significant  differences  between  them,  their  overall  assessments,  based  on  AGREE 
Instrument,  were  very  different.  Therefore  the appraisers  reached  a  consensus  that  we 
would hereafter use only the overall  assessment  method of the AGREE Instrument  for 
characterizing  the  acceptance  of  the  methodological  quality  of  CPG,  rather  than  the 
mentioned  statistical  methods.  Assessors  had  judged  that  the  AGREE Instrument  is  a 
useful tool and is applicable for the general assessment of methodological quality of CPGs 
in  laboratory  medicine  as  well.  Surprisingly  the  well-known  CPGs  had  some  serious 
shortcomings in all appraised aspects, thus reflected need for appraising of methodological 
quality of all CPGs before their use. 
Table 1 Inter-rater agreement and rating quality of CPGs based on pair-wise comparison of domain 
scores in the DM pilot study
Domain Score (%) 
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WHO 1999  41 11 8 38 13 24 Not recommend 0,03* 3 
NICE 2001 95 94 82 90 36 52 Strongly recommend  - 1 
NACB 2002 52 31 43 76 28 19 Recommend with alteration 0,097   1
+ 
ADA 2003 70 30 32 73 22 7 Recommend with alteration    0,060** 2 
Mean Domain 
Score (%) 70 39 45 63 28 35     
ICC 0.78 0.91 0.86 0.76 0.02† 0.68     
Cronbach's α  0.78 0.88 0.90 0.77 0.23† 0.63       
 
* significant (p≤0,05);  ** notable difference (but not significant); †: not acceptable; + difference is not statistically significant
5.2. Methodological quality of clinical practice guidelines
5.2.1. Diabetes mellitus (Paper III)
Based on the assessment of methodological quality, 22 CPGs were recommended by 
reviewers, of which only 11 were strongly recommended and the  rest “with provisos and 
alterations” (Table 2). Overall, the best performing domains were D1 “Scope and purpose”. 
Although D4 “Clarity and presentation” scored highly only 10 CPGs (38%) were supported
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Table 2 Critical appraisal of diabetes mellitus guidelines by the AGREE Instrument
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AAFP 1999 (30) 89 40 69 35 17 21 Recommend with alteration
SIGN 2001 (31) 56 75 74 71 8 71 Strongly recommend
NAC 2002 (32) 47 6 17 33 14 4 Would not recommend
NACB 2002 (33) 53 23 31 67 11 17 Recommend with alteration 
NICE BG 2002 (34) 92 85 87 98 33 42 Strongly recommend
NICE L 2002 (35) 92 88 90 98 33 42 Strongly recommend
SEMDSA 2002 (36) 14 23 6 56 0 0 Would not recommend
SOGC 2002 (37) 81 21 40 73 19 13 Recommend with alteration 
CDA 2003 (38) 86 33 60 90 25 42 Recommend with alteration
NZG 2003 (39) 86 83 76 96 56 100 Strongly recommend
USPSTF T2 2003 (40) 97 21 77 90 39 88 Strongly recommend
USPSTF GDM 2003 (41) 94 23 74 81 42 83 Strongly recommend
WHO T2 2003 (42) 100 33 29 52 58 42 Recommend with alteration
ACP 2004 (43) 97 27 64 79 6 75 Recommend with alteration
Kaiser P 2004 (44) 42 27 6 65 0 0 Would not recommend
NICE T1 2004 (45) 97 88 92 98 72 92 Strongly recommend
GPAC 2005 (46) 72 35 13 85 69 29 Recommend with alteration
IDF T2 2005 (47) 58 46 55 79 44 96 Recommend with alteration
NHMRC 2005 (48) 97 73 90 81 39 21 Strongly recommend
WHO DG 2006 (49) 78 15 26 69 25 21 Wouldn't recommend
AACE 2007 (50) 64 42 39 69 17 46 Recommend with alteration
ADA 2007 (51) 61 31 39 92 39 0 Recommend with alteration
IDF BG  2007 (52) 86 27 55 60 28 9 Recommend with alteration
PRODIGY L 2007 (53) 97 71 64 90 56 21 Strongly recommend
PRODIGY R 2007 (54) 97 69 67 88 56 21 Strongly recommend
PRODIGY BG 2007 (55) 75 71 67 81 72 29 Strongly recommend
Mean Domain Score (%) 77 45 54 76 34 39
Range (%) 14-100 6-88 6-92 33-98 0-72 0-100
No of CPGs with DS more 
than 60% 20 9 15 22 3 7
Percentage of CPGs with 
DS more than 60% 77 35 58 85 11 27
Overall assessment
Domain Score (%)
CPG and date of issue 
(ref)
with tools for  application.  In  D3, which explored the rigour  of development,  there are 
notable  shortcomings  in  using  systematic  methods  for  searching  the  evidence  and 
providing  information  on  the  literature  retrieval  and  selection  process;  indicating  the 
methods  used  for  formulating  recommendations;  and  giving  information  on  the  peer 
reviewing  and  updating  process.  Domain  2,  which  explored  stakeholder  involvement, 
showed lower scores. Low scores were achieved with in the “Applicability” (34%) and  
“Editorial independence” (39%) domains, in which each item performed very poorly. The  
wide spread of the minimum and maximum scores of each individual domain these data in 
all domains demonstrated unexpectedly large variation in CPG.
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Table 3 Critical appraisal of NSCLC guidelines by the AGREE Instrument 
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ACCP (56) 61 46 60 46 6 75 Recommend  with alterations
ANDEM (57) 89 25 10 71 0 25 Not recommend
ASCO (58) 94 50 71 67 17 75 Recommend with alterations
ATS-ERS (59) 44 4 5 29 0 8 Unsure
BTS-SCG (60) 100 33 60 79 6 83 Recommend with alterations
CIGNA (61) 67 13 12 54 11 8 Unsure
EGTM (62) 44 4 2 29 0 0 Unsure
FNCLCC (63) 94 54 57 79 17 33 Recommend with alterations
NACB (64) 50 17 29 54 11 25 Not recommend
SIGN (65) 89 75 76 75 33 25 Recommend with alterations
SPLF (66) 61 46 48 38 17 8 Not recommend
Mean Domain Score (%) 72 33 39 56 11 33
Range (%) 44-100 4-75 2-76 29-79 0-33 0-83
No of CPGs with DS more 
than 60% 8 1 4 5 0 3
Percentage of CPGs with 
DS more than 60% 73 9 36 45 0 27
Domain score (%)
CPG (ref) Overall assessments
5.2.2. Non-small cell lung cancer (Paper II)
Only 5 out of 11 CPGs were recommended for use by assessors and none achieved  
the  best  overall  quality  rating  of„strongly  recommend”  (Table  3).  Three  CPGs  were 
„wouldn’t recommend” and for 3 CPGs the quality was difficult to assess („unsure”) by 
appraisers. Overall,  the best performing domain was D1 “Scope and purpose” and D4 
“Clarity  and  presentation”.  There  were  notable  shortcomings  in  other  domains  which 
explored the rigour of development, stakeholder involvement and editorial independence.  
Domain  5,  which  explored  the  applicability  of  recommendations,  showed  the  lowest 
scores. In all domains, except Domain 5, there was a large of scores. 
5.3. Causes of poor methodological quality of diabetes mellitus guidelines
5.3.1. Correlation between  the  characteristics  and methodological  quality  clinical 
practice guidelines (Paper III)
Date of publication
Most CPGs were developed after 2002 and only 2 were developed between 1999 
and 2001. Only the highest scoring D1 and D4 showed some marginal development in 
quality over the time scale investigated (Table 2). However, the poor performance in D6 
showed  further  deterioration  from  2005  onwards  with  failures  to  report  editorial 
independence and conflict of interest in the majority of CPGs.  
Type of publication 
There  was  diversity  in  definitions:  19  publications  were  labelled  as  CPGs or 
recommendations,  of  which  7  stated  that  they were  evidence-based,  4  were  position 
statements or reports, and 3 guidance documents (Table 4).  Amongst the 7 CPGs that 
claimed to be evidence-based 5 had evidence summaries and 6 graded their 
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Table 4 Characteristics of DM CPGs
CPG (ref)
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AAFP (30) 1999 Both Diagnostic >100 no  USA review of the evidence and recommendations + - - -
SIGN (31) 2001 Database Combined 51-100 yes UK national clinical guidelines - + + 3
NAC (32) 2002 Journal Combined  1-10 no North America consensus report - - - 1
NACB (33) 2002 Both Diagnostic 11-50 no  USA guidelines and recommendations - + + -
NICE BG (34) 2002 Database Combined >100 yes UK clinical guidelines and evidence review + + + 4
NICE L (35) 2002 Database Combined >100 yes UK clinical guidelines and evidence review + + + 4
SEMDSA (36) 2002 Database Combined  1-10 no South Africa guideline - - - -
SOGC (37) 2002 Both Diagnostic  1-10 no Canada clinical practice guidelines - + + -
CDA (38) 2003 Database Combined >100 no Canada clinical practice guidelines - + + -
NZG (39) 2003 Database Combined >100 yes New Zealand evidence-based best practice guidelines - + + 3
USPSTF T2 (40) 2003 Database Diagnostic 51-100 yes USA recommendation and rationale statement + + + -
USPSTF GDM (41) 2003 Database Diagnostic >100 yes USA recommendation and rationale statement + + + -
WHO T2 (42) 2003 Database Diagnostic 51-100 yes International report - - - -
ACP (43) 2004 Both Combined  1-10 yes  USA clinical practice guidelines + - - 5
Kaiser P (44) 2004 Database Combined  1-10 no USA, Canada guidelines - - - -
NICE T1 (45) 2004 Database Combined >100 yes UK clinical guidelines and evidence review + + + 4
GPAC (46) 2005 Database Diagnostic 11-50 yes Canada guidelines and protocols - - - 3
IDF T2 (47) 2005 Database Combined 51-100 yes International global guideline - + -  3-5
NHMRC (48) 2005 Database Diagnostic >100 yes Australia evidence based guidelines + + + 3
WHO DG (49) 2006 Database Diagnostic 51-100 yes International report - - - -
AACE (50) 2007 Both Combined >100 yes USA medical guidelines (evidence based) - + + -
ADA (51) 2007 Both Combined 11-50 yes  USA position statement - + + 1**
IDF BG  (52) 2007 Database Diagnostic 0-50 yes International guideline - + + 3
PRODIGY L (53) 2007 Database Combined 51-100 yes UK guidance - + + Con.
PRODIGY R (54) 2007 Database Combined 51-100 yes UK guidance - + - Con.
PRODIGY BG (55) 2007 Database Combined 51-100 yes UK guidance - + + Con.
Percentage of 
CPGs fulfilling 
criteria
31 69 62 58
*: Guideline development manual or technical document was available before CPG publication; **: Information on updating is provided  
in a separate guideline development manual,Con.: Continuous
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Table 5 Subgroup analysis
Domains 
Scope and purpose Stakeholder involvement 
Rigor of 
development 
Clarity and 
presentation Applicability 
Editorial 
independence Str
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DS (%) SE Range DS (%) SE Range DS (%) SE Range DS (%) SE Range DS (%) SE Range DS (%) SE Range No (%) 
No 
(%) 
No 
(%) 
Guideline database  
(n=19) 80 5.2 14-100 52 6.1 15-88 58 6.5 6-92 80 3.3 52-98 40 5.1 0-72 45 7.6 0-100 
11  
(58) 
5 
(26) 
3  
(16) 
Source 
Journal and GL 
database (n=7) a 70 7.1 47-97 27 4.6 6-42 43 6.8 17-69 64 8.3 33-92 18 3.9 6-39 25 10.0 0-75 
0  
(0) 
6 
(86) 
1 
(14) 
  P=   0.209   0.055   0.169   0.083   0.018**   0.152      
Diagnostic (n=10) 85 4.5 53-100 31 5.2 15-73 50 8.2 13-90 69 5.3 35-90 35 5.8 11-69 34 8.9 9-88 3 (30) 
6 
(60) 
1  
(10)  Scope 
Combined (n=16) 73 6.2 14-97 54 6.8 6-88 56 6.9 6-92 80 4.5 33-98 33 6.1 0-72 43 8.8 0-100 8 (50) 
5 
(31) 
3  
(19) 
  P=   0.286   0.023**   0.660   0.097   0.776   0.551      
1-50 pages                       
(n=9) 61 8.5 14-97 24 2.7 6-35 30 7.0 6-64 68 5.8 33-92 21 7.4 0-69 16 8.0 0-75 
0 
(0) 
6 
(67) 
3 
(33) 
Length 
>50 pages                
(n=17) 86 3.5 56-100 56 6.2 15-88 67 4.8 26-92 80 4.1 35-98 41 4.6 8-72 52 7.2 21-100 
11  
(65) 
5 
(29) 
1 
(6) 
  P=   0.009*   0.003*   0.001*   0.051   0.018**   0.001*       
North America   
(n=12) 74 5.7 42-97 27 2.8 6-42 44 7.1 6-77 72 5.7 33-92 25 5.5 0-69 35 9.3 0-88 
2 
(17) 
8 
(66) 
2 
(17) 
British                                     
(n= 7 ) 87 5.9 56-97 62 3.2 69-88 67 4.5 64-92 82 3.8 71-98 42 8.9 0-72 44 10.1 0-92 
7 
(100) 
0 
(0) 
0 
(0) Origin   
Other                             
(n= 7) 74 11.3 14-100 43 9.8 15-83 48 11.2 6-90 70 5.9 52-96 36 7.6 0-58 41 15.4 0-100 
2 
(28.5) 
3 
(43) 
2 
(28.5) 
  P=   0.355   0.001*   0.028**   0.037**   0.112   0.606       
yes (n=19) 84 3.5 56-100 53 5.9 15-88 62 5.3 52-98 82 3.0 50-98 42 4.5 6-72 49 7.4 0-100 11  (58) 
7 
(37) 
1 
(5 ) Manual 
no (n=7) 59 10.5 14-89 25 4.0  6-40 33 9.5  6-69 60 7.7  33-90 12 3.6  0-25 14 5.6  0-42 0  (0) 
4  
(57) 
3 
(43) 
  P=  0.013**   0.015**   0.022**   0.010*   0.001*   0.004*      
 
a One guideline was published in journal only; * p≤0.01; **p≤0.05
recommendations.  Three CPGs that had evidence tables,  however,  did not define their  
publications  as  being  evidence-based.  Over  two  thirds  of  CPGs defined  their  grading 
system but only 16 graded their final recommendations. 
Procedure for updating guidelines
Fifteen CPGs (58%) gave a timescale or expiry date (Table 4). The most frequent  
review date was 3 and 4 years. Only 10 CPGs (38%) provided adequate information on  
the updating process.  
Sub-grouping by source 
Grouping CPGs by source of publication revealed that one CPG was published in a 
peer-reviewed  journal,  19  were  available  in  electronic  CPG  databases  and  6  in  both 
sources.  The  CPG that  was  published exclusively  in  a  peer-reviewed  journal  was  not 
recommended for  use by the assessors.  None  of  the 6  CPGs published  both in  peer-
reviewed journals and CPG databases were strongly recommended. CPGs published in 
electronic  guideline  databases  only,  received  a  more  favourable  overall  assessment.  
Notable  difference,  at a level  of significance  of  p≤0.05,  could be observed  in  the D5 
Applicability domain only for the electronic CPGs (Table 5). 
Sub-grouping by length
A  clear  relationship  could  be  demonstrated  between  CPG  length  and 
methodological quality (Table 5). Most CPGs that were not recommended were shorter 
and  all  strongly  recommended  guidelines  were  longer  than  50  pages.  Significant 
differences between these subgroups could be found for most domains with higher quality 
of  the  longer  CPGs.  However,  the  best  performing  CPGs,  scoring  >50%  in  the 
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“Applicability” domain were generally longer than 50 pages and all were published in 
electronic databases (Table 2 and 4)
Sub-grouping by origin 
Nine CPGs originated from the USA, 3 from Canada, 7 from the UK, one from 
Australia, New-Zealand and South Africa and 4 were international. The majority of the 
strongly recommended CPGs originated from the UK. Significant  differences (p≤0.01) 
could be observed in fulfilling the criteria of the D2 “Stakeholder involvement” domain,  
with higher scores for the British CPGs. 
Sub-grouping by the availability of guideline methods manual
Two thirds of CPGs had some accompanying manuals describing the methods of 
their development in some form. All strongly recommended CPGs had such a manual. All 
mean domain scores were better in the subset where these manuals were available.
5.3.2. Methodological quality of primarily diagnostic and combined clinical practice 
guidelines (Paper III)
The rate of occurrence of strongly recommended CPGs and the not recommended 
CPGs was also higher  for  the combined,  than for  the diagnostic  CPGs (Table 5).  The 
quality of purely diagnostic CPGs was not significantly different from that of combined 
CPGs based on their domain scores (Table 6). 
5.3.3. Compliance of guidelines with basic diagnostic reporting standards 
(Paper III) 
Only  about  60  percent  of  the  CPGs  mentioned  essential  laboratory-specific 
information  (Table  7)  in  any  detail.  Reporting  these  pieces  of  information  was  more 
frequent  in  diagnostic  as  compared  to  combined CPGs,  but  the  difference  was  not 
statistically significant in the various CPG subgroups (Table 8).
Table 6   AGREE item scores in diagnostic and combined diabetes mellitus guidelines 
Mean Score SE Mean Score SE
1 The overall objective of the guideline is specifically described. 3.75 0.2 3.08 0.2 0.023**
2 The clinical questions covered by the guideline are specifically described. 3.43 0.2 3.00 0.2 0.421
3 The patients to whom the guideline is meant to apply are specifically described. 3.45 0.2 3.45 0.2 0.897
4 The guideline development team involves all relevant professional groups. 2.30 0.2 2.67 0.2 0.241
5 The patients' views and preferences have been sought. 1.58 0.3 2.45 0.3 0.060
6 The target users of the guideline are clearly defined. 2.63 0.2 3.28 0.2 0.047**
7 The guideline has been piloted among target users. 1.23 0.2 2.08 0.2 0.220
8 Systematic methods were used to search for evidence. 2.63 0.2 2.42 0.2 0.551
9 The criteria for selecting the evidence are clearly described. 2.48 0.3 2.39 0.3 0.660
10 The methods used for formulating the recommendations are clearly defined. 2.08 0.2 2.44 0.2 0.391
11 The health benefits, side effects and risks have been considered. 3.28 0.2 3.06 0.2 0.391
12 There is an explicit link between the recommendations and the supporting evidence. 3.18 0.3 3.08 0.3 0.938
13 The guideline has been externally reviewed by experts prior to its publication. 2.43 0.2 2.67 0.2 0.856
14 A procedure for updating the guideline is provided. 1.55 0.3 2.78 0.3 0.041**
15 The recommendations are specific and unambiguous. 3.38 0.1 3.69 0.1 0.363
16 The different options for management of the condition are clearly presented. 3.23 0.1 3.45 0.1 0.182
17 The recommendations are easily identifiable. 3.78 0.1 3.73 0.1 0.150
18 The guideline is supported with tools for application. 1.95 0.3 2.73 0.3 0.220
19 The potential barriers in applying the recommendations have been discussed. 1.95 0.2 1.83 0.2 0.452
20 The potential cost implications of applying the recommendations have been considered. 2.75 0.2 1.88 0.2 0.041**
21 The guideline presents key review criteria for monitoring and/or audit purposes. 1.43 0.3 2.28 0.3 0.623
22 The guideline is editorially independent from the funding body. 2.60 0.3 2.59 0.3 1.000
23 Conflicts of interest of guideline development members have been recorded. 1.95 0.3 1.95 0.3 0.979
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Table 7 Diabetes mellitus guidelines reporting laboratory-specific criteria
CPG and date of issue 
(ref)
Prevalence / 
Pre-test 
probability
Diagnostic 
accuracy
Preanalytical 
information
Analytical 
information
AAFP 1999 (30) - + - -
SIGN 2001 (31) + + - +
NAC 2002 (32) - - - -
NACB 2002 (33) + + + +
NICE BG 2002 (34) -  + -  +
NICE L 2002 (35) - - - -
SEMDSA 2002 (36) - - - -
SOGC 2002 (37) + + + +
CDA 2003 (38) + + + +
NZG 2003 (39) + - + +
USPSTF T2 2003 (40) + + + +
USPSTF GDM 2003 (41) + + + +
WHO T2 2003 (42) + + - -
ACP 2004 (43) - - - -
Kaiser P 2004 (44) - - - -
NICE T1 2004 (45) - + + +
GPAC 2005 (46) - - + -
IDF T2 2005 (47) + + + +
NHMRC 2005 (48) + + + +
WHO DG 2006 (49) + + + -
AACE 2007 (50) + -  + -
ADA 2007 (51) + + + +
IDF BG  2007 (52) - - - -
PRODIGY L 2007 (53) - - + +
PRODIGY R 2007 (54) + + + +
PRODIGY BG 2007 (55) + - + +
Percentage of CPGs 
fulfilling criteria 58 58 62 58
Table 8 Qualitative analysis of reporting laboratory specific information in diabetes mellitus 
guidelines
  Percentage of guidelines fulfilling criteria 
    Prevalence 
Diagnostic 
accuracy 
Preanalytical 
information 
Analytical 
information 
Guideline database  (n=19) 58 58 63 63 
Source Journal and database (n=7) a 57 57 57 43 
  P=   0.973 0.973 0.780 0.407 
Diagnostic (n=10) 70 80 70 50 Scope Combined (n=16) 50 44 56 63 
  P=   0.428 0.109 0.683 0.689 
0-50 pages (n=9) 33 33 44 33 Length >50 pages (n= 17) 71 71 71 71 
  P=   0.103 0.103 0.234 0.103 
Yes (n=19) 63 58 68 63 Manual No (n=7) 43 57 43 43 
  P=   0.407 0.973 0.369 0.407 
North America (n=12) 58 58 67 50 
British (n=7) 43 57 57 86 Origin  
Other (n=7) 71 57 57 43 
  P=   0.556 0.998 0.884 0.205 
 
a = one guideline published in journal only
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Table 9 Studies investigating the methodological quality of CPGs by the AGREE Instrument 
Mean Domain Scores (%) Study (ref) Topics covered 
by the CPGs 
Publication 
date of 
CPGs  
Origin of 
CPGs 
No. 
of 
CPG D1 D2 D3  D4   D5    D6   
Comments 
AGREE 2003 (9) mixed 1992-1999 international* 33 69 36 41 66 37 30 
*:CPG origin : 10 from  European 
countries and 1 from Canada 
Burgers et al. 2003 (67) mixed 1992-1999 international* 86 66 34 37 57 31 48 
*: CPG origin :10 European 
countries and Canada (62 
deifferent agencies and 
organisations) 
Harpole et al. 2003 (17) lung cancer 1989-2001 international 51 72 35 52 57 20 24  
Brosseau et al. 2004 
(68) 
musculosceletal 
physiotherapy 1998-2002 
French or 
English 9 64 54 49 60 29 24 
 
Burgers et al. 2004 (18) non-oncolgy 1992-1999 international 68 65 30 29 52 30 41  
van Tulder et al. 2004 
(19) 
acute low back 
pain in primary 
care 
1987-2001 international* 17 79 50 52 76 28 28 
*CPG origin:: 4 USA, 3 Canada, 1 
UK,  1 Israel, 2 Netherlands, 1 
Germany, 1 Sweden, 1 New 
Zealand, 1 Finland, 1 Switzerland, 
1 Denmark, 
Burgers et al. 2004 (18) 
Fervers et al. 2005 (69) 
oncology 1992-1999 international* 32 63 34 42 57 26 47 
*CPG origin: 13 countries 
Boluyt et al. 2005 (70) pediatrics 1990-2005 mostly North American * 17 84 42 54 78 19 40 
*CPG origin: 13 US A, 3 Canada, 
1 Scotland 
Horvath et al. 2005 
(PaperI) diagnosis of DM 1990-2003 international* 4 64 41 41 69 25 25 
*CPG origin: 2 USA, 1 UK, 1 
WHO               
Lindberg et al. 2005 
(71) 
Swedish CPG on 
diabetes mellitus not stated local* 1 
78 
(73) 
30 
(67) 
14 
(37) 
61 
(72) 
31 
(60) 
72 
(60) 
* Östergötland county; 
percentages in parentheses 
represent evaluation by lay 
persons 
Lindberg et al. 2005 
(71) 
Swedish CPG on 
asthma /allergy not stated local* 1 
50 
(67) 
25 
(25) 
9 
(13) 
71 
(56) 
26 
(30) 
8 
(0) 
* Östergötland county; 
percentages in parentheses 
represent evaluation by lay 
persons 
Navarro Puerto et al. 
2005 (72) Spanish CPGs 1999-2002 national 61 31 18 18 25 13 38 
Domain scores are an 
approximation of the true mean, 
reconstructed from the available 
original data.  
Presztoczki et al. 2005 
(73) 
Hungarian CPGs 
on management of 
DM 
1993-2004 national 9 78 17 12 54 39 0 
Thesis, unpublished 
Stiegler et al. 2005 (74) psychiatric 
treatment 1998-2003 international* 61 33 31 48 71 23 20 
*CPGs origin: 14 European 
countries  
Arnau et al. 2006 (75) 
diagnosis and 
treatment of low 
back pain 
1994-2002 international 17* 63 38 32 53 21 22 
*11 guidelines common with the 
study by van Tulder et al. (19) 
2004  
Cates et al. 2006 (76) occupational health 2004 USA 1 80 46 27 87 31 29  
Ministry of Health, 
Hungary 2006 (77) 
Hungarian care 
pathway protocols 2005-2006 national 180 72 30 28 74 37 8 
Internal evaluation for the 
Ministry of Health; unpublished 
Vervey  et al. 2006 (78) suicide attempts 1995-2005* local in the Netherlands 27 43 22 12 65 15 ** 
*starting date is not precisely 
defined; **not used in this study 
for being considered irrelevant 
Watine et al. 2006 
(Paper III) 
laboratory tests in 
lung cancer 1997-2003 international* 11 72 33 39 56 11 33 
*CPG origin: 5 USA, 3 France, 2 
UK, 1 EU 
Nagy et al. 2007 
(Lecture VII) 
diagnosis and 
monitoring of DM 1999-2005 international* 26 74 41 50 70 27 35 
*CPG origin: 13 USA, 3 Canada 6 
UK, 1 Australia, 1 New Zealand, 
1 South Africa, 1 WHO 
(unpublished) 
TOTAL/MEAN    712 65 34 34 63 26 30  
 
D1: Scope and purpose; D2: Stakeholder involvement; D3: Rigour of development; D4: Clarity and presentation; D5: Application,  
D6: Editorial independence.
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5.4. Methodological quality of clinical practice guidelines in other medical fields 
(Book chapter II)
We found 21 studies up till 2007 which, have investigated the quality of CPGs using the  
AGREE Instrument  in  various  clinical  fields (Table  9).  The altogether  712 CPGs had 
recommendations in diverse medical fields. Majority of these CPGs were predominantly 
therapeutic.  The  maximum and minimum values  of  mean domain  scores  from the  21 
studies are presented in a diagram in conjunction with our own results for the DM and 
NSCLC CPGs (Figure 2). The heterogeneity is very large between these 21 studies. Our 
results for CPGs related to laboratory medicine were similar to there international findings.  
Despite the heterogeneity of the published data, the major shortcomings were very similar 
in each study and domain. The only notable difference in our finding was that the NSCLC 
CPGs reached lower scores in each domain, than the DM CPGs. 
Figure 2 Fulfilment of AGREE criteria of CPGs based on mean domain scores of 21 studies in 
different medical fields.
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5.5. Correlation between guideline methodological quality and validity of content 
(Paper II)
We collected the recommendations about the use of laboratory tests in these NSCLC 
CPGs (Table  10)  and  information  from existing  systematic  reviews  on the  laboratory 
parameters to be measured during the pre-treatment evaluation of NSCLC patients (Table  
11).  Recent systematic reviews provide no evidence that measurement of tumor markers 
in routine practice would improve NSCLC patients’ outcomes. Only 4 CPGs, which did 
not recommend the use of tumor markers, were scored for validity of content as “good”. 
Regarding the other laboratory tests, only 5 CPGs recommended clearly most of  
the laboratory tests which were found to be useful by previously published systematic  
reviews. These CPGs were scored “good” for validity of content about laboratory tests.  
Results  of  our  comparison  of  guideline  quality  versus content  for  each  guideline  are 
shown in Table 12. We did not find any relationship between the quality and validity of 
content and scope of CPGs (containing only diagnostic or therapeutic recommendations,  
as well). Our results did not confirm any relationship between the date of publications and 
the scores of quality or the validity of content.
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Table 10 Recommendations of eleven CPGs for use of laboratory tests in the pretreatment 
management of NSCLC patients.
CPG (ref) Recommended Unclear recommendation Not recommended
ACCP (56)
Hematocrit, ALP, calcium, 
electrolytes, glucose, GGT, 
SGOT
Other routine laboratory tests None
ANDEM (57) Leucocyte count, albumin, SR, calcium, ALP, LD None Tumor markers
ASCO (58) Hemoglobin, leucocyte counts, LD, ALP, calcium
Other routine chemistries, liver 
function tests
LASA, CA 19-9, DNA index, 
DNA flow cytometric 
proliferation analysis, p53 
tumor supressor gene, as 
oncogene
ATS-ERS (59)
Blood counts, electrolytes, 
albumin, calcium, ALP, 
transaminases, bilirubin, 
creatinine
None Tumor markers
BTS-SCG (60) Albumin, creatinine, glucose None None
CIGNA (61) * None None CEA, NSE, cyfra 21-1
EGTM (62) * cyfra 21-1, CEA** CA 125, TPA None
FNCLCC (63)
Hemoglobin, leucocyte counts 
with differential, LD, albumin, 
calcium
None Tumor markers
NACB (64) * None cyfra 21-1, CEA, NSE None
SIGN (65) ALP, calcium
Other biochemistry and 
hematology tets, liver function 
tets
None
SPLF (66) * None cyfra 21-1 CEA
*: CPGs intended for tumor markers only
**: Only in cases of adenocarcinoma or large cell carcinoma
Table 11 Laboratory variables that should be measured for the pre-treatment evaluation of NSCLC 
patients based on previously published systematic reviews
Purpose of test Variables to be measured
Evaluation of toxicity (or 
tolerance) to treatments
In all patients:
hemoglobin,  leucocyte  counts  with  differential, 
platelets,  electrolytes,  glucose,  creatinine, 
transaminases, bilirubin, albumin
Pretreatment prognostic 
evaluation
In all patients:
hemoglobin  (if  radiation  therapy),  leucocyte  counts 
with  differential,  lactate  dehydrogenase,  albumin, 
calcium
In patients participating in therapeutic trials:
hemoglobin, leukocyte counts with differential, lactate 
dehydrogenase, albumin, calcium, NSE
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Table 12 Correlation between methodological quality and validity of content of NSCLC CPGs
Tumor markers Other laboratory tests
ACCP (56) Good Not so good Good
ANDEM (57)* Not so good Good Good
ASCO (58) Good Not so good Good
ATS-ERS (59)* Dubious Good Good
BTS-SCG (60)* Good Not so good Not so good
CIGNA (61)* Dubious Good  
EGTM (62)* Dubious Not so good  
FNCLCC (63) Good Good Good 
NACB (64)* Not so good  Not so good  
SIGN (65) Good Not so good Not so good
SPLF (66)* Not so good Not so good  
CPGs (ref) Methodological quality
Validity of content of recommendation
*: diagnostic CPG only
6. DISCUSSION
6.1. AGREE Instrument as a critical appraisal tool for diagnostic clinical practice 
guidelines
Findings of our pilot study confirmed that the AGREE Instrument is an easy-to-learn 
and easy-to-use critical appraisal tool for assessing methodological quality of CPGs and is 
applicable to laboratory related CPGs as well. Our observations highlighted the need for at 
least 2 but preferably 3 or 4 independent reviewers. Assessor should reach consensus to 
avoid bias due to subjectivity of judgement in the rating of performance in each domain  
and for overall acceptance of guidelines for use in practice. 
6.2. Methodological quality of clinical practice guidelines  
Irrespective of  the topic of CPGs we found large variation in the way diagnostic 
recommendations in CPGs are developed and how methodological quality is incorporated 
in the development process. We found severe shortcomings of methodological quality in 
CPGs for the management of DM and NSCLC. Most of the guideline groups did not use  
systematic  and  rigorous  development  processes  and  did  not  involve  target  users  and 
patients in formulating recommendations. There were serious weaknesses in applicability 
and editorial independence of recommendations. 
A notable number of diagnostical CPGs (15% in DM and 27% in NSCLC), including 
some of the most accepted CPGs worldwide (e.g. WHO in DM and NACB in NSCLC),  
were not recommended for use in practice by the AGREE evaluation as they failed to meet  
basic quality criteria. These findings raise concern about both the internal and the external  
validity of international recommendations even when they are issued by highly reputed 
authorities. The heterogeneity in quality highlights the need for critical evaluation of every 
document before recommendations are used in clinical practice.
Our  evaluation  revealed  that  CPGs developed  by  prestigious  authorities  in  many 
other  disciplines  suffer  from  the  same  methodological  weaknesses  as  diagnostic 
recommendations in the field of DM and NSCLC. Our literature review revealed relatively 
high  number  of  CPGs (n=712)  critically  appraised  by  the  AGREE Instrument.  Large 
proportion of these CPGs predominantly had therapeutic recommendations. Therefore we 
can conclude that the quality of laboratory related CPGs did not differ from therapeutic 
CPGs. Since some studies did not report the scores of individual CPGs but only quoted 
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mean scores  of  their  evaluations,  we  could only compare  the mean domain  scores  of 
published studies. Despite these limitations our findings depict a similar picture across 
studies  in  many  medical  fields  independently  of  date  of  publication  or  origin  of 
recommendations.  Shortcomings  in  methodological  quality  are  mostly  due  to  lack  of 
rigour  or  inappropriate  reporting  of  the  CPG  development  process,  and  lack  of 
applicability and declaration of editorial independence. Our results are the first in the field  
of diagnostic because no studies published so far investigated the quality of diagnostic  
recommendations. 
6.3. Causes of poor methodological quality of diagnostic guidelines for diabetes 
mellitus
Some studies investigated the probable reasons of methodological shortcomings but 
not one has evaluated these reasons in diagnostic CPGs and not one studied the reporting 
of  laboratory  related  information  in  guidelines  yet.  This  question  was  addressed  by 
subgroup analyses of our study on DM CPGs. Our findings demonstrated that longer and 
electronically published CPGs and the availability of CPG development manuals yielded 
higher methodological scores in most AGREE domains. One simple explanation is the 
lack  of  space  available  for  detailed  and  accurate  reporting  of  CPG  methodology  in  
journals. Paradoxically, lengthy CPGs are thought to be less practical for daily use, so one  
may argue that the length of CPGs adversely affects implementation. In our case, CPGs 
that achieved high scores for “Applicability” were indeed longer documents, but they also 
covered additional information on organization, cost implications and monitoring of the 
use of recommendations in practice. All these tools help CPG implementation and thus, at 
least in principle, we cannot confirm that lengthy CPGs are not applicable in practice. The 
Conference on Guideline Standardization defined a standard for CPG reporting in order to 
promote quality and facilitate implementation. Such CPG reporting standards have not yet 
been adopted by most journals, and peer-reviewers also rarely use the AGREE or other  
criteria for systematic assessment of recommendations prior to publication. 
In our study the quality of purely diagnostic CPGs was not significantly different 
from that of combined diagnostic and therapeutic CPGs. Our additional evaluation has 
shown that nearly half of all diagnostic CPGs do not report pre-analytical, analytical and 
diagnostic accuracy data, which may lead to inappropriate requesting and interpretation of  
tests in clinical practice. Fulfilling these criteria would  be desirable in any CPGs that  
provide  laboratory  testing-related  recommendations,  since  it  is  expected  that  practice 
guidelines are developed in a multidisciplinary process.  Unfortunately this could not be 
confirmed by our study as only 41% of the criteria were fulfilled in D2 which explored the 
involvement of all relevant stakeholders in the CPG development process. 
All CPGs that achieved higher scores in the comparison by origin were from agencies 
that had detailed CPG manuals which provided a clear description and standards for the 
development  process.  The  availability  of  a  CPG  manual,  however,  does  not  always  
guarantee that CPG teams follow those processes consistently, and it has been shown that  
it  is  often  not clear how decisions are  made by the CPG team when arriving at  final  
recommendations. The substantial heterogeneity,  both in how the type of publication is 
defined and the adherence to this definition in the final presentation of the CPG, suggests 
that there is likely to be a disparity between the methodology CPG developers described 
and what  is  actually  followed  in practice.  We found,  for  example,  several  CPGs that  
described a grading  system but did not grade their final recommendations. The lack of 
evidence  tables  in  CPGs that  claim to be evidence-based  may also point  to  potential  
deviations from the processes set in CPG manuals. 
Such heterogeneity of definitions of guidelines may highlight different approaches in 
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formulating recommendations for practice. We also found several CPGs that, while having 
proof of using evidence-based methods, failed to define their publication as such.  This 
suggests  that  the  definitions  used  in  the  international  guideline  community  may  be  
confusing  for  both  guideline  developers  and  users,  and  that  simplification  and 
standardization of terminology is needed. 
Even  though  guideline  development  methods  have  gradually  improved  and  were 
published  by several  organisations,  we  could  not  demonstrate  major  improvements  in 
CPG  quality  for  most  domains  and  in  the  “Editorial  independence”  domain  even 
deterioration in scores was observed over time. 
There are several limitations in our study. By evaluating English publications only,  
our results may suffer from language bias. However, several publications, including our 
own  review of  the  topic,  confirm  no  significant  differences  in  the  quality  of  English 
versus non-English publications of guidelines or trials. Since most national DM CPGs are 
based on or strongly influenced by international recommendations primarily published in 
English, we believe our results are likely to be generalizable. Shortcoming of all critical  
appraisal  tools  is  that  they  do  not  differentiate  between  whether  the  publication  fails  
certain criteria due to lack of reporting or to poor methodology and design. Therefore, our 
results should not be interpreted as criticisms of the truth of scientific statements or the  
validity  of  recommendations  made  in  a  given  publication  about  DM.  However,  the 
demonstrated shortcomings in reporting and/or the methodology applied by different CPG 
developers could lead to distrust in and/or misuse of recommendations. 
6.4. Correlation between guideline methodological quality and validity of content 
A  number  of  studies  confirm  the  assumption  that  CPGs  of  poor  methodological 
quality potentially transmit biased opinions that may cause unnecessary burden to patients 
and costs to society. Others, however, demonstrated that despite the high inconsistencies in 
formulating recommendations and the great variation in the supporting evidence cited, the 
agreement in the content of recommendations was remarkable. Our results have shown that  
guidelines with poor methodological quality are not necessarily invalid in their content and 
vice versa; high quality CPGs do not necessarily provide the best recommendations. 
The  discrepancy  between  methodological  quality  and  clinical  validity  of 
recommendations could be explained by the authors using different pieces of evidence or  
differing judgements to base their statements on. The reasons for this could be manifold: 
(a)  non-systematic  searching  for  the  evidence,  (b)  ignoring  findings  that  confirm  the 
beliefs  and assumptions  or  the experience  and practice  of  the guidelines  development  
group, (c) other competing interests as priorities, or (d) considered judgements taking into  
account  other  influencing  factors  such  as  costs,  organizational  barriers,  patients’ 
preferences, ethics, and safety.  It has to be acknowledged that the evidence is only one  
element in formulating recommendations. Guideline developers may down- or upgrade the 
strength of evidence in final recommendations if other reasons (e.g. social, economical,  
organizational, societal,  ethical, patient perspectives, safety or legal) strongly justify it.  
However, considered judgement and grading should be a well-documented and transparent 
process  so  that  users  of  CPGs  understand  the  rationale  and  reasoning  behind  final  
recommendations and why and to what  extent  guideline teams decided to direct from 
research findings. 
The other reason of this discrepancy might be that the quality of a guideline depends 
not only on the rigour of its development but also on the quality of the evidence base  
underlying  the  recommendations.  A  number  of  studies  confirmed  this  assumption 
demonstrating that poor of high quality evidence was used for CPGs in different medical  
fields and especially in oncology, such as  in CPGs for lung cancer.  
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Our study has a limitation because it focused on a small part of an oncology topic. 
Therefore our data cannot be generalized to other medical topics. The AGREE Instrument  
or  other  CPG  appraisal  tools  can  neither  investigate  the  accuracy  of  the  content  of 
recommendations nor their impact on patient outcomes.  Nevertheless the discrepancies 
found in our study between quality and content highlight the need for critical appraisal of  
not  only the methodology but  also the content  of recommendation before  their use in 
practice. Conflicting recommendations on the use of laboratory tests are likely to lead to a  
waste of laboratory resources and might even cause harm to patients. Effective treatment 
depends on the effective use of diagnostic tests, and if diagnostic recommendations are not  
evidence based, it is reasonable to assume that therapeutic interventions will sometimes be 
initiated and monitored inappropriately.
7. SUMMARY
In our studies we could demonstrate that: 
• There is  large  variation  in  the way diagnostic  recommendations  in  guidelines  for 
clinical practice are developed and how methodological quality is incorporated in the 
development process. 
• The methodological shortcomings of DM and NSCLS CPGs are very similar to those 
in other medical fields. 
• There are serious shortcomings in involving all relevant stakeholders in the guideline 
development  process,  in  the  rigour  of  development,  applicability  and  editorial  
independence and these raise concern about both the internal and the external validity  
of recommendations.
• The quality of purely diagnostic CPGs was not significantly different from that of  
combined CPGs for DM.  
• Subgroup  analyses  of  our  DM study  demonstrated  that  longer  and  electronically 
published  CPGs and  the  availability  of  CPG development  manuals  yielded  better 
overall methodological quality with higher scores in most AGREE domains. 
• Nearly half of all DM CPGs do not report pre-analytical, analytical and diagnostic 
accuracy data, which may lead to inappropriate reporting and interpretation of tests in 
clinical practice. 
• Diagnostic  recommendations about tumor markers  are conflicting in CPGs for  the 
managements of NSCLS patients. 
• We did not find any straight forward relationship between methodological quality and 
validity of content of NSCLS CPGs. 
• Our findings  highlight the need for critical evaluation of both the methodology and 
content of any CPG before recommendations are put in clinical practice.
In conclusions, we make the following recommendations for the future:
• There is  a need for  systematically  developed,  explicit  recommendations  based on 
evidence-based  guideline  development  and  reporting  standards  in  laboratory 
medicine. 
• To overcome  the  methodological  shortcomings  of  current  guidelines  standardized 
methods  for  making  evidence-based  guideline  recommendations  need  to  be 
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disseminated more effectively in laboratory medicine. 
• Evidence should always  be assessed in close collaboration between clinicians and 
specialists  in  laboratory  medicine.  Evidence  should  be  only  one  element  n 
formulating recommendations.  Interpretation  of the evidence and its translation to 
practical recommendations should be documented explicitly and transparently and 
must be free from any form of vested interest or bias
• There is a need for simplification and standardization of CPGs terminology.
• A unified system for grading diagnostic recommendations might help to improve the 
validity of resulting recommendations. 
• Further studies are needed to explore in depth the relationship between the scientific 
validity and the methodological quality of diagnostic recommendations.
• All  CPGs  should  be  critically  evaluated  for  methodology  and  content  before 
recommendations are used in clinical practice. 
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